|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Genzyme |
|---|---|
| Information provided by: | Genzyme |
| ClinicalTrials.gov Identifier: | NCT00196742 |
Purpose
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The objectives of the Registry are:
| Condition |
|---|
|
Fabry Disease |
| Study Type: | Observational |
| Study Design: | Cohort |
| Official Title: | Fabry Disease Registry |
| Study Start Date: | April 2001 |
The Fabry Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact:
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
All patients with a confirmed diagnosis of Fabry disease are eligible for inclusion in the Registry.
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Fabry Registry HelpLine | 800-745-4447 ext 15500 | help@fabryregistry.com |
| Contact: Fabry Registry HelpLine | 617-591-5500 | help@fabryregistry.com |
| United States, Massachusetts | |
| Registry participation is worldwide and not limited to this facility; facilities not yet active may enroll upon identification of a patient. | Recruiting |
| Cambridge, Massachusetts, United States, 02142 | |
| Study Director: | Medical Monitor | Genzyme |
More Information
| Responsible Party: | Genzyme Coporation ( Medical Monitor ) |
| Study ID Numbers: | Fabry Registry |
| Study First Received: | September 13, 2005 |
| Last Updated: | September 22, 2009 |
| ClinicalTrials.gov Identifier: | NCT00196742 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
alpha Galactosidase A aGAL Fabry GL3 |
Anderson-Fabry Disease angiokeratomas GLA deficiency errors in metabolism |
|
Fabry Disease Lipid Metabolism, Inborn Errors Sphingolipidoses Metabolic Diseases Lysosomal Storage Diseases, Nervous System Lysosomal Storage Diseases Nervous System Diseases Central Nervous System Diseases |
Brain Diseases Metabolism, Inborn Errors Genetic Diseases, Inborn Genetic Diseases, X-Linked Brain Diseases, Metabolic, Inborn Lipidoses Lipid Metabolism Disorders Brain Diseases, Metabolic |